Publicacions en col·laboració amb investigadors/es de Centro Nacional de Investigaciones Oncológicas (47)

2024

  1. CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts

    OncoImmunology, Vol. 13, Núm. 1

  2. Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates

    Toxicology and Applied Pharmacology, Vol. 487

2023

  1. A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response

    OncoImmunology, Vol. 12, Núm. 1

  2. Correlation Between Endoglin and Malignant Phenotype in Human Melanoma Cells: Analysis of hsa-mir-214 and hsa-mir-370 in Cells and Their Extracellular Vesicles

    Advances in experimental medicine and biology, Vol. 1408, pp. 253-272

  3. Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 18, pp. 3744-3758

  4. Improved Sensitivity in BRAFV600E Detection in Combined Tissue and Extracellular Vesicle-Based Liquid Biopsy in Melanoma

    Journal of Investigative Dermatology, Vol. 143, Núm. 8, pp. 1606-1610

2022

  1. Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies

    Therapeutic Advances in Medical Oncology, Vol. 14

2021

  1. An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad antitumor activity in humanized murine cancer models without toxicity

    Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3167-3177

  2. FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1

    Breast Cancer Research, Vol. 23, Núm. 1

  3. Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics

    EMBO Molecular Medicine, Vol. 13, Núm. 12

2020

  1. Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state

    Nature Medicine, Vol. 26, Núm. 12, pp. 1865-1877

2019

  1. Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAFV600E mutation

    Journal of Experimental Medicine, Vol. 216, Núm. 5, pp. 1061-1070

  2. p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors

    Cancer Cell, Vol. 35, Núm. 1, pp. 46-63.e10

2017

  1. DEK oncogene is overexpressed during melanoma progression

    Pigment Cell and Melanoma Research, Vol. 30, Núm. 2, pp. 194-202

  2. Systems analysis identifies melanoma-enriched pro-oncogenic networks controlled by the RNA binding protein CELF1

    Nature Communications, Vol. 8, Núm. 1

  3. Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine

    Nature, Vol. 546, Núm. 7660, pp. 676-680

2016

  1. Analysis of paired primary-metastatic hormone-receptor positive breast tumors (HRPBC) uncovers potential novel drivers of hormonal resistance

    PLoS ONE, Vol. 11, Núm. 5

  2. Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers

    Nature Communications, Vol. 7

2015

  1. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors

    Molecular Carcinogenesis, Vol. 54, Núm. 7, pp. 566-576

  2. RAB7 counteracts PI3K-driven macropinocytosis activated at early stages of melanoma development

    Oncotarget, Vol. 6, Núm. 14, pp. 11848-11862